Место акарбозы в лечении и профилактике сахарного диабета 2 типа. Новые возможности снижения сердечно-сосудистого риска

Неуклонный рост числа больных сахарным диабетом (СД) тип 2, отмеченный на протяжении последних десятилетий, делает проблему профилактики и лечения этого заболевания приоритетным направлением медицины. Показано, что особое внимание следует уделять раннему выявлению нарушений углеводного метаболизма, на стадии нарушения толерантности к глюкозе. Коррекция образа жизни и рациональная диетотерапия, а также использование препарата акарбозы (Глюкобая) позволяют достигнуть стойкой нормогликемии и более чем в трети случаев предупредить развитие СД. Помимо этого, лечение акарбозой положительно влияет на показатели свертывающей системы крови, липидный спектр, уменьшает дисфункцию эндотелия, выраженность оксидативного стресса, уровень инсулина и проинсулина за счет снижения постпрандиальной гликемии и инсулинорезистентности тканей. Вследствие этих эффектов отмечаются уменьшение массы тела, риска развития артериальной гипертензии, инфаркта миокарда и всех сердечно-сосудистых событий. Таким образом, целесообразно более широко использовать акарбозы у больных с предиабетом, а также у больных с СД 2 типа как в качестве монотерапии при наличии постпрандиальной гипергликемии, так и в качестве второго препарата в случае отсутствия стойкой нормогликемии. Подчеркивается, что акарбоза может сочетаться с любым сахаропонижающим препаратом. Использование акарбозы способствует превенции СД 2 типа и сердечно-сосудистых событий.

сахарный диабет тип 2, постпрандиальная гликемия, сердечно-сосудистый риск

1. Engelgau M., Narayan K., Herman W. Screening for type 2 diabetes // Diabetes Care. - 2000. - Vol. 23, № 10. - P. 1563-1580.

2.

3. Harris R., Donahue K., Rathore S.S. et al. Screening adults for type 2 diabetes: review of the evidence for the U.S. Preventive Services Task Force // Ann. Intern. Med. - 2003. - Vol. 138, № 3. - P.215-229.

4.

5. Johnson S.L., Tabaei B.P., Herman W.H. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age // Diabetes Care. - 2005. - Vol. 28, № 2. - P.307-311.

6.

7. Nathan M.D., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Clin. Diabet. - 2009. - Vol. 27, № 1. - P. 4-14.

8.

9. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. U.S. Preventive Services Task Force // Ann. Intern. Med. - 2003. - Vol. 138, № 3. - P. 212-214.

10.

11. Ceriello A., Colagiuri S. International diabetes federation guideline for management of postmeal glucose: review of recommendations // Diabet. Med. - 2008. - Vol. 25, № 10. - P. 1151-1156.

12.

13. Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно-сосудистых и других неинфекционных заболеваний среди трудоспособного населения России // Кардиоваск. терапия и профилактика. - 2002. - № 3. - С. 4-8.

14.

15. Шестакова М.В. Сахарный диабет и ишемическая болезнь сердца: влияние инсулинорезистентности и ее коррекции на сердечнососудистый прогноз // Болезни сердца и сосудов. - 2006. - № 2. - С. 4-7.

16.

17. Diabetes mellitus: a major risk factor for cardiovascular disease: a joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association // Circulation. - 1999. - Vol. 100, № 10. - P. 1132-1133.

18.

19. Bartnik M., Malmberg K., Hamsten A. et al. Abnormal glucose tolerance - a common risk factor in patients with acute myocardial infarction in comparison with population-based controls // J. Intern. Med. - 2004. - Vol. 256, № 4. - P. 288-297.

20.

21. Haffner S.M., Lehto S., Rönnemaa T. et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction // N. Engl. J. Med. - 1998. - Vol. 339, № 4. - P. 229-234.

22.

23. Malmberg K., Yusuf S., Gerstein H.C. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry // Circulation. - 2000. - Vol. 102, № 9. - P. 1014-1029.

24.

25. Mathew V., Wilson S.H., Barsness G.W. et al. Comparative outcomes of percutaneous coronary interventions in diabetics vs non-diabetics with prior coronary artery bypass grafting // Eur. Heart J. - 2002. - Vol. 23, № 18. - P. 1456-1464.

26.

27. Phillips P.J. Women, coronary artery disease and diabetes // Aust. Fam. Physician. - 2008. - Vol. 37, № 6. - P. 441-442.

28.

29. Savarese V., Ahmed I., Goldstein B.J. Coronary artery disease screening in patients with diabetes // Endocrine. - 2008. - Vol. 54, № 11. - P. 1184-1192.

30.

31. Otter W., Kleybrink S., Doering W. et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus // Diabet. Med. - 2004. - Vol. 21, № 2. - P. 183-187.

32.

33. Stratton I., Adler A.I., Neil H.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study // Br. Med. J. - 2000. - Vol. 321, № 7258. - P. 405-412

34.

35. Daemen J., Kuck K.H., Macaya C. et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial // J. Am. Coll. Cardiol. - 2008. - Vol. 52, № 24. - P. 1957-1967.

36.

37. Alssema M., Dekker J.M., Nijpels G. et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study // Diabetes Care. - 2005. - Vol. 28, № 4. - P. 860-865.

38.

39. Dunder K., Lind L., Zethelius B. et al. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study // Br. Med. J. - 2003. - Vol. 326, № 7391. - P. 681-683.

40.

41. Hirai F.E., Moss S.E., Klein B.E., Klein R. Relationship of glycemic control, exogenous insulin, and c-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) // Diabetes Care. - 2008. - Vol. 31, № 3. - P. 493-497.

42.

43. Rosak C., Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system // Curr. Diabet. Res. - 2009. - Vol. 5, № 3. - P. 157-164.

44.

45. Yudkin J.S. increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes // Circulation. ‒ 2002. ‒ Vol. 106, № 24. ‒ P. e202.

46.

47. Yudkin J.S., May M., Elwood P. et al. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study // Diabetologia. - 2003. - Vol. 45, № 3. - P. 327-336.

48.

49. Zethelius B., Lithel H., Hales C.N. et al. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp // Diabetologia. - 2005. - Vol. 48, № 5. - P. 862-867.

50.

51. Благосклонная Я.В., Шляхто Е.В., Красильникова Е.И. Метаболический сердечно-сосудистый синдром // Ученые записки. - 2002. - Т. IХ, № 3. - С. 111-115.

52.

53. Красильникова Е.И., Благосклонная Я.В., Шляхто Е.В. Атеросклероз. Проблемы патогенеза и терапии. - СПб.: Медицинская литература, 2006. - С. 137-163.

54.

55. Чазова И.Е., Мычка В.Б. Метаболический синдром. - М.: Медиа Медика, 2004. - 168 с.

56.

57. Шляхто Е.В., Баранова Е.И., Беляева О.Д., Большакова О.О. Метаболический синдром: прошлое, настоящее, будущее // Эфферентная терапия. - 2007. - Т. 13, № 1. - С. 74-78.

58.

59. Шляхто Е.В. и др. Инсулинорезистентность артериальная гипертензия. Современные подходы к лечению // Клиническая и экспериментальная кардиология. - СПб.: Изд-во ООО « Академический медицинский центр», 2005. - С. 188-198.

60.

61. Pyorala K., Savolainen E., Kaukola S., Haapakoski J. Plasma insulin and coronary heart disease risk factor relationship to other risk factors and predictive value during 9.5-year follow-up of the Helsinki Polismen Study population // Acta Med. Scand. - 1985. - Vol. 701. - P. 38-52.

62.

63. Fontbonne A., Charles M.A., Thibult N. et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up // Diabetologia. - 1991. - Vol. 34, № 5. - P. 356-361.

64.

65. Cullen K., Stenhouse N., Wearne K., Welborn T. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton. Western Australia-13 year study // J. Chronic Dis. - 1983. - Vol. 36, № 5. - P. 371-377.

66.

67. Соколов Е.И. Сахарный диабет и атеросклероз. - М.: Медицина, 1996. - 215 c.

68.

69. Крылов А.Л. Ангиопластика коронарных артерий у больных // Кардиология. - 2008. - Т. 48, № 12. - С. 55-58.

70.

71. Aljada A., Ghanim H., Mahanty P. et al. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factors and matrix metalloproteinase in mononuclear cells, and in plasmatissue factor and concentrations // Am. J. Clin. Nutr. - 2004. - Vol. 80, № 1. - P. 51-57.

72.

73. Ceriello A., Quagliaro L., Piconi L. et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment // Diabetes. ‒ 2004. ‒ Vol. 53, № 3. ‒ P. 701-710.

74.

75. Chen H.F., Li C.Y. Effect-modifications by age and sex on the risks of coronary artery disease and revascularization procedures in relation to diabetes // Diabetes Res. Clin. Pract. - 2007. - Vol. 75, № 1. - P. 88-95.

76.

77. Dhindsa S., Tripathy D., Mohanty P. et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factors - kB in mononuclear cells // Metabolism. - 2004. - Vol. 53, № 3. - P. 330-334.

78.

79. Kawano H., Motoyama T., Hirashima O. et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery // J. Am. Coll. Cardiol. ‒ 1999. ‒ Vol. 34, № 1. ‒ P. 146-154.

80.

81. Monnier L., Mas E., Ginet C. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes // J. Am. Med. Assoc. - 2006. - Vol. 295, № 14. - P. 1681-1687.

82.

83. Scognamiglio R., Negut C., De Kreutzenberg S.V. et al. Postprandial myocardial perfusion in healthy subjects and in Type 2 diabetic patients // Circulation. - 2005. - Vol. 112, № 2. - P. 179-184.

84.

85. Hanefeld M., Koehler C., Shaper F. et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals // Atherosclerosis. - 1999. - Vol. 144, № 1. - P. 229-235.

86.

87. Cavalot F., Petrelli A., Traversa M. et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study // J. Clin. Endocrinol. Metab. - 2006. - Vol. 91, № 3. - P. 813-819.

88.

89. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria // Arch. Intern. Med. - 2001. - Vol. 161, № 3. - P. 397-405.

90.

91. Hanefeld M., Cagatay M., Petrowitsch T. et al. Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies // Eur. Heart. J. - 2004. - Vol. 25, № 1. - P. 10-16.

92.

93. Hanefeld M., Fischer S., Julius U. et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up // Diabetologia. - 1996. - Vol. 39, № 12. - P. 1577-1583.

94.

95. Nakagami T., Qiao Q., Tuomilehto J. et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study // Eur. J. Cardiovasc. Prev. Rehabil. - 2006. - Vol. 13, № 4. ‒ P. 555-561.

96.

97. Milicevic Z., Raz I., Strojek K. et al. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D) study design // J. Diabetes. Complications. - 2005. - Vol. 19, № 2. - P. 80-87.

98.

99. Raz I., Wilson P.W.F., Strojek K. et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: The HEART2D trial // Diabetes Care. - 2009. - Vol. 32, № 3. - P. 381-386.

100.

101. Джелинжер П. Постпрандиальная гипергликемия и сердечно-сосудистый риск // Сахарный диабет.‒ 2004.‒ Т. 23, №2.‒ С. 4-10.

102.

103. Alssema M., Schindhelm R.K., Dekker J.M. et al. Postprandial glucose and not triglyceride concentrations are associated with carotid intima media thickness in women with normal glucose metabolism: the Hoorn prandial study // Atherosclerosis. - 2008. - Vol. 196, № 2. - P. 712-719

104.

105. American Diabetes Association. Clinical practice recommendations 2007: diagnosis and classification of diabetes mellitus// Diabetes Care.‒ 2007.‒ Vol. 30 (suppl. 1).‒ P. S42-S47.

106.

107. Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes // Diabetes Care. - 1997. - Vol. 20, № 12. - P. 1822-1826.

108.

109. Levitan E.B., Song Y., Ford E.S., Liu S. Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies // Arch. Intern. Med. - 2004. - Vol. 164, № 19. - P. 2147-2155.

110.

111. Shiraiwa T., Kaneto H., Miyatsuka T. et al. Postprandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese Type 2 diabetic patients // Biochem. Biophys. Res. Commun. - 2005. - Vol. 336, № 1. - P. 339-345.

112.

113. Woerle H.J., Neumann С., Zschau S. et al. Impact of fasting and postprandial glycemia on overall glycemic control in Type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels // Diabetes Res. Clin. Pract. - 2007. - Vol. 77, № 2. - P. 280-285.

114.

115. Ceriello A Postprandial hyperglycemia and diabetes complications: is it time to treat? // Diabetes.‒ 2005.‒ Vol. 54, № 1.‒ P. 1-7.

116.

117. Esposito K., Giugliano D., Nappo F. et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus // Circulation. - 2004. - Vol. 110, № 2. - P. 214-219.

118.

119. Shimabukuro M., Chinen I., Niga N. еt al. Effects of dietary composition on postprandial endothelial function and adiponectin concentrations in healthy humans: a crossover controlled study // Am. J. Clin. Nutr. - 2007. - Vol. 86, № 4.‒ P. 923-928.

120.

121. Khaw K.T., Wareham N., Luben R. et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk) // Br. Med. J. - 2001. - Vol. 322, № 7277. - P. 15-18.

122.

123. Eschwege E., Richard J.L., Thibult N. et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later // Horm. Metab. Res. - 1985. - Vol. 15. - P. 41-46.

124.

125. Temelkova-Kurktschiev T.S., Koehler C., Henkel E. et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level // Diabetes Care. - 2000. - Vol. 23, № 12. - P. 1830-1834

126.

127. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada // Can. J. Diabetes. ‒ 2003. ‒ Vol. 27 (suppl. 2). ‒ P. S1-S152

128.

129. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus// Endocr Pract.‒ 2007.‒ Vol. 13 (suppl. 1).‒ P. 1-68.

130.

131. Nathan D., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy // Diabetes Care. - 2009. - Vol. 32, № 1. - P. 193-205.

132.

133. Nathan D.M., Buse J.B., Davidson M.B. et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. - 2006. - Vol. 29, № 8. - P. 1963-1972.

134.

135. Мкртумян А.М. К вопросу о профилактике сахарного диабета типа 2 // Сахарный диабет. - 2003. - Т. 16, № 3. - С. 48‒50.

136.

137. Шестакова М.В., Брескина О.Ю. Акарбоза в профилактике сахарного диабета типа 2 // Сахарный диабет. - 2003. - Т. 19, № 2. - С. 38‒41.

138.

139. Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) // Diabetes Care. - 1999. - Vol. 22, № 6. - P. 960-964.

140.

141. Chiasson J.L., Josse R.G., Gomis R. et al. A carbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance // J. Am. Med. Assoc. - 2003. - Vol. 290, № 4. - P. 486-494.

142.

143. Brand-Miller J.C., Petocz P., Colagiuri S. et al. Meta-analysis of low-glycemic index diets in the management of diabetes: response to Franz // Diabetes Care. - 2003. - Vol. 26, № 12. - P. 3363-3364.

144.

145. McMillan-Price J., Petocz P., Atkinson F. et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial // Arch. Intern. Med. - 2006. - Vol. 166, № 14. - P. 1466-1475.

146.

147. Opperman A.M., Venter C.S., Oosthuizen W. et al. Meta-analysis of the health effects of using the glycaemic index in meal-planning // Br. J. Nutr. - 2004. - Vol. 92, № 3. - P. 367-381.

148.

149. Wolever T.M., Yang M., Zeng X.Y. et al. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals // Am. J. Clin. Nutr. - 2006. - Vol. 83, № 6. - P. 1306-1312.

150.

151. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes in patients with lifestyle intervention or metformine // N. Engl. J. Med. ‒ 2002. ‒ Vol. 346, № 6-7. ‒ P. 393-403.

152.

153. Tuomilehto J., Lindström J., Eriksson J.G. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance // N. Engl. J. Med. ‒ 2001. ‒ Vol. 344, № 18. ‒ P. 1343-1350.

154.

155. Coniff R.F., Shapiro J.A., Seaton T.B., Bray G.A. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide-plus-acarbose in NIDDM // Am. J. Med. - 1995. - Vol. 98, № 5. - P. 443-451.

156.

157. Chiasson J.L., Josse R.G., Leiter L.A. et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance // Diabetes Care. ‒ 1996. ‒ Vol. 19, № 11. - P. 1190-1193.

158.

159. Schnell O., Chan J., Josse R.G. Therapeutic experience with acarbose in the treatment of type 2 diabetes // Diabetes. ‒ 2009. - Vol. 18, № 5. ‒ P. 3-9.

160.

161. Delgado H., Lehmann T., Robbioni-Harsch E. et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetes patients // Diabetes Metab.- 2002.- Vol. 28, № 3.- P. 195-200.

162.

163. Iwase M., Iida M. Acarbose-feeding increases pancreatic islet blood flow in obese glucose- intolerant OLETF rats // Diabetes. - 2008. - Vol. 57 (suppl. 1). - P. 412.

164.

165. Wolever T.M., Singer W., Chiasson J.L. et al. Acarbose improves abnormal insulin metabolism in type 2 diabetes // Clin. Res. - 1993. - Vol. 41. - P. 360A.

166.

167. Yamamoto M., Otsuki M. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats // Metabolism. - 2006. - Vol. 55, № 4. - P. 533-540.

168.

169. UKPDS Group: UK Prospective diabetes study 16: overview of six years' therapy of type 2 diabetes: a progressive disease // Diabetes. - 1995. - Vol. 44, № 11. - P. 1249-1258.

170.

171. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 358, № 24. - P. 2560-2572.

172.

173. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. ‒ 2009. ‒ Vol. 360, № 2. ‒ P. 129-139.

174.

175. Koster I., von Ferber L., Ihle P. et al. The cost burden of diabetes mellitus: the evidence from Germany - the CoDiM Study // Diabetologia. - 2006. - Vol. 49, № 7. - P. 1498-1504.

176.

177. The action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 358, № 24. - P. 2545-2559.

178.

179. o 90. Whiteley L., Padmanabhan S., Hole D., Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey // Diabetes Care. ‒ 2005. ‒ Vol. 28, № 7. ‒ P. 1588-1593.

180.

181. Chiasson J.L., Comis R., Hanefeld M. et al. The stop-NIDDIV trial: An International study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rational, design and preliminary screening data // Diabetes Care. ‒ 1998. ‒ Vol. 21, № 10. ‒ P. 1720-1725.

182.

183. Derosa G., Salvadeo S.A., D'Angelo A. et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial // Curr. Med. Res. Opin. - 2009. - Vol. 25, № 3. - P. 607-615.

184.

185. Hanefeld M., Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits // Expert Rev. Cardiovasc. Ther. - 2008. - Vol. 6, № 2. - P. 153-163.

186.

187. Maghal M.A., Menon M.Y., Zardari M.K. et al. Effect of acarbose on glycemic control serum lipids and lipoproteins in type 2 diabetes // J. Pak. Med. Assoc. - 2000. - Vol. 50. - P. 152-156.

188.

189. Rosak C. The use of acarbose as combination therapy for type 2 diabetics // Diabetes Metabetes Heart. - 2007. - Vol. 16. - P. 119-126.

190.

191. Ceriello A., Taboga C., Tonutti I. et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose // Diabetologia. - 1996. - Vol. 39, № 4. - P. 469-473.

192.

193. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose // Diabetes. - 2004. - Vol. 53 (suppl. 2). - P. A189.

194.

195. Rudofski G., Reismann P., Schickofer S. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs // Horm. Metab. Res. - 2004. - Vol. 36. - P. 630-638.

196.

197. Wang X. Comparison of serum C-reactive protein level in different glucose tolerant subjects and the change in serum CRP level in IGT subjects with acarbose // Chin J. Endocrinol. Metab. - 2003. - Vol. 19. - P. 254-256.

198.

199. Ceriello A., Taboga C., Tonutti L. еt al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment // Circulation. - 2002. - Vol. 106, № 10. - P. 1211-1218.

200.

201. Baron A.D., Eckel R.H., Schmeiser L., Kolterman O.G. The effect of short term a-glucosidase inhibition on carbohydrate and lipid metabolism in type II diabetics // Metabolism. - 1987. - Vol. 36, № 5. - P. 409-415.

202.

203. Kado S., Murakami T., Aoki A. et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus // Diabetes Res. Clin. Pract. - 1998. - Vol. 41, № 1. - P. 49-55.

204.

205. Kelley D.E., Bidot P., Freedman Z. et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes // Diabetes Care. - 1998. - Vol. 21, № 12. - P. 2056-2061.

206.

207. Ogawa S., Takeuchi K., Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes // Diabetes Obes. Metabol. - 2004. - Vol. 6, № 5. - P. 384-390.

208.

209. Steiner G. Hyperinsulinemia and hypertriglyceridemia // J. Int. Med. - 1994. - Vol. 736. - P. 23-26.

210.

211. Stolar M.W. Atherosclerosis in diabetes: the role of hyperinsulinemia // Metabolism. - 1988. - Vol. 37, № 2 (suppl. 1). - P. 1-9.

212.

213. Tushuizen M.E., Diamant M., Heine R.J. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes // Postgrad. Med. J. - 2005. - Vol. 81, № 951. - P. 1-6.

214.

215. Holman R.R., Blackwell L., Manley S. et al. Results from the early diabetes intervention trial // Diabetes. - 2003. - Vol. 52 (suppl. 1). - P. A16.

216.

217. Phillips P.J., Karrasch J., Scott R. et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin // Diabetes Care. ‒ 2003. ‒ Vol. 26, № 2. ‒ P. 269-273.

218.

219. Rosenstock J., Brown A., Fischer J. et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes // Diabetes Care. - 1998. - Vol. 21, № 12. - P. 2050-2055.

220.

221. Sumual A.R., Pandelaki K., Rotty L.A.W. Acarbose-Metformin combination versus metformin alone // J. Asian Fed. Endocr. Soc. - 2003. - Vol. 21. - P. 24-31.

222.

223. Laar van de F.A. Diet and alpha-glucosidase inhibition in the early treatment of type 2 diabetes mellitus. - Nijmegen: Drukkerij Quick-print, 2008. - 137 p.